Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05054725 · ClinicalTrials.gov registry record · Phase 2
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
A Phase 2 study, sponsored by Revolution Medicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT05054725 is a Phase 2 study that has completed, run by Revolution Medicines. The registered enrollment target is 47 participants.
The verdict
NCT05054725, a Phase 2 study, has completed, sponsored by Revolution Medicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
Interventions
- DRUG Sotorasib
- DRUG RMC-4630
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-12-30 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05054725
The ClinicalTrials.gov registry entry for NCT05054725 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sotorasib is the first listed.
NCT05054725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05054725 about?
NCT05054725 is a clinical study titled "Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies". The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
What is the current status of trial NCT05054725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2021-12-30. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT05054725?
The interventions under investigation include: Sotorasib (DRUG), RMC-4630 (DRUG).
Who is sponsoring clinical trial NCT05054725?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.